calpain and Sarcoma

calpain has been researched along with Sarcoma* in 3 studies

Other Studies

3 other study(ies) available for calpain and Sarcoma

ArticleYear
A calpain-6/YAP axis in sarcoma stem cells that drives the outgrowth of tumors and metastases.
    Cell death & disease, 2022, 09-24, Volume: 13, Issue:9

    Sarcomas include cancer stem cells, but how these cells contribute to local and metastatic relapse is largely unknown. We previously showed the pro-tumor functions of calpain-6 in sarcoma stem cells. Here, we use an osteosarcoma cell model, osteosarcoma tissues and transcriptomic data from human tumors to study gene patterns associated with calpain-6 expression or suppression. Calpain-6 modulates the expression of Hippo pathway genes and stabilizes the hippo effector YAP. It also modulates the vesicular trafficking of β-catenin degradation complexes. Calpain-6 expression is associated with genes of the G2M phase of the cell cycle, supports G2M-related YAP activities and up-regulated genes controlling mitosis in sarcoma stem cells and tissues. In mouse models of bone sarcoma, most tumor cells expressed calpain-6 during the early steps of tumor out-growth. YAP inhibition prevented the neoformation of primary tumors and metastases but had no effect on already developed tumors. It could even accelerate lung metastasis associated with large bone tumors by affecting tumor-associated inflammation in the host tissues. Our results highlight a specific mechanism involving YAP transcriptional activity in cancer stem cells that is crucial during the early steps of tumor and metastasis outgrowth and that could be targeted to prevent sarcoma relapse.

    Topics: Animals; beta Catenin; Bone Neoplasms; Calpain; Cell Line, Tumor; Humans; Mice; Microtubule-Associated Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Osteosarcoma; Sarcoma; YAP-Signaling Proteins

2022
Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence.
    JCI insight, 2018, 09-06, Volume: 3, Issue:17

    Sarcomas are still unsolved therapeutic challenges. Cancer stem cells are believed to contribute to sarcoma development, but lack of specific markers prevents their characterization and targeting. Here, we show that calpain-6 expression is associated with cancer stem cell features. In mouse models of bone sarcoma, calpain-6-expressing cells have unique tumor-initiating and metastatic capacities. Calpain-6 levels are especially high in tumors that have been successfully propagated in mouse to establish patient-derived xenografts. We found that calpain-6 levels are increased by hypoxia in vitro and calpain-6 is detected within hypoxic areas in tumors. Furthermore, calpain-6 expression depends on the stem cell transcription network that involves Oct4, Nanog, and Sox2 and is activated by hypoxia. Calpain-6 knockdown blocks tumor development in mouse and induces depletion of the cancer stem cell population. Data from transcriptomic analyses reveal that calpain-6 expression in sarcomas inversely correlates with senescence markers. Calpain-6 knockdown suppresses hypoxia-dependent prevention of senescence entry and also promotion of autophagic flux. Together, our results demonstrate that calpain-6 identifies sarcoma cells with stem-like properties and is a mediator of hypoxia to prevent senescence, promote autophagy, and maintain the tumor-initiating cell population. These findings open what we believe is a novel therapeutic avenue for targeting sarcoma stem cells.

    Topics: Animals; Autophagy; Biomarkers; Calpain; Carcinogenesis; Cell Line, Tumor; Cellular Senescence; Disease Models, Animal; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Hypoxia; Male; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Nanog Homeobox Protein; Neoplasms; Neoplastic Stem Cells; Octamer Transcription Factor-3; Sarcoma; SOXB1 Transcription Factors; Xenograft Model Antitumor Assays

2018
DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.
    PLoS genetics, 2011, Volume: 7, Issue:4

    Albeit genetically highly heterogeneous, muscular dystrophies (MDs) share a convergent pathology leading to muscle wasting accompanied by proliferation of fibrous and fatty tissue, suggesting a common MD-pathomechanism. Here we show that mutations in muscular dystrophy genes (Dmd, Dysf, Capn3, Large) lead to the spontaneous formation of skeletal muscle-derived malignant tumors in mice, presenting as mixed rhabdomyo-, fibro-, and liposarcomas. Primary MD-gene defects and strain background strongly influence sarcoma incidence, latency, localization, and gender prevalence. Combined loss of dystrophin and dysferlin, as well as dystrophin and calpain-3, leads to accelerated tumor formation. Irrespective of the primary gene defects, all MD sarcomas share non-random genomic alterations including frequent losses of tumor suppressors (Cdkn2a, Nf1), amplification of oncogenes (Met, Jun), recurrent duplications of whole chromosomes 8 and 15, and DNA damage. Remarkably, these sarcoma-specific genetic lesions are already regularly present in skeletal muscles in aged MD mice even prior to sarcoma development. Accordingly, we show also that skeletal muscle from human muscular dystrophy patients is affected by gross genomic instability, represented by DNA double-strand breaks and age-related accumulation of aneusomies. These novel aspects of molecular pathologies common to muscular dystrophies and tumor biology will potentially influence the strategies to combat these diseases.

    Topics: Aneuploidy; Animals; Calpain; Cells, Cultured; Comparative Genomic Hybridization; Disease Models, Animal; DNA Damage; Dysferlin; Dystrophin; Female; Humans; Membrane Proteins; Mice; Mice, Inbred C57BL; Models, Animal; Muscle Proteins; Muscle, Skeletal; Muscular Dystrophies; Mutation; N-Acetylglucosaminyltransferases; Sarcoma

2011